Researchers combine cancer drugs to fight melanoma
- 5 years ago
CAMBRIDGE, MASSACHUSETTS — Scientists have combined two experimental cancer drugs to treat melanoma.
As part of a study published in the journal Molecular Cancer Therapeutics, researchers paired protein kinase inhibitors and ribonuclease before releasing them onto cancerous tumors.
The protein kinases inhibitors work to bind and block the functions of enzymes that have been affected by cancer cells. This slows the spread of the disease. The ribonuclease then works to enter the tumor and destroy its RNA.
The study found that the drug combination worked more effectively to treat melanoma than individual treatments of each drug.
As part of a study published in the journal Molecular Cancer Therapeutics, researchers paired protein kinase inhibitors and ribonuclease before releasing them onto cancerous tumors.
The protein kinases inhibitors work to bind and block the functions of enzymes that have been affected by cancer cells. This slows the spread of the disease. The ribonuclease then works to enter the tumor and destroy its RNA.
The study found that the drug combination worked more effectively to treat melanoma than individual treatments of each drug.